Biobanking for Medical R&D: Technology and Market 2010-202522 Sep 2011 • by Natalie Aster
It is difficult to have a comprehensive figure on the number of biobanks currently existing across the world. This is due to the fact that large collections of biological samples are presently stored in research laboratories, with those samples being difficult to account for. Also, there is a lack of any common platform to access information on the various biobanks and their stored specimens. We can only assess the market on the basis of number of internationally recognised national biobanks and small biobanks affiliated to regional, national or international networks or involved in partnership with other biobanks for increased sharing of resources.
Europe is currently leading the world in biobanking. It has a number of national biobank networks to coordinate the research efforts and promote biobanking. Some of these include:
• Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE);
• BrainNet Europe.
Currently in its preparatory phase, Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) is a pan-European agency for achieving greater harmonisation in biobanking processes and providing greater access to biobank resources for progressing research. It intends to integrate the existing biobanks, their resources and enabling technologies.
The report “Biobanking for Medical R&D: Technology and Market 2010-2025” by Visiongain reveals the opportunities and challenges the biobanking sector will face. These include consolidation and harmonisation of biobanking practices. The report analyses strengths, weaknesses and revenue trends for biobanking from 2010 to 2025.
Published: August 2010
Price: US$ 2,461.00
Report Sample Abstract
Stem Cell Banking Overview
Stem cell banks collect, test and cryopreserve stem cells from donors either for preparation of cell lines for use in research, or for future use through banking umbilical cord blood. The storage of stem cells, usually in the form of cord blood stored for potential future personal usage, is a growing market, particularly in the US.
As stem cells gain in prominence in the public mind, the practice of banking umbilical cord blood, and of banking one's own blood stem cells, will become more widespread. Those processes will become more prevalent when stem cell therapies become more widespread, from this decade onwards.
Use of stem cells is now a well-recognised component of assays for toxicity testing and drug development. New research indicates that stem cells may also have the power to advance the study of disease progression in vitro. Laboratory supply of stem cells is a promising market that many companies are entering. Toxicity and other drug development assays are among the principal laboratory applications for stem cells.
Revenue Forecast for Total Stem Cell Banking, 2010-2025
Visiongain believes that the segment's revenue growth will continue to increase during the forecast period, but with prices falling as the number of banks proliferates and the battle for customers becomes fiercer.
The growth in the market is currently driven by umbilical cord blood banking. In 2009, the Obama administration lifted a ban on federal funding for research into embryonic stem cell lines imposed by the previous administration. The liberalisation of US federal government policy towards stem cell research will increase the demand of stem cells for research, strengthening the stem cell banking market, we conclude. Still, much uncertainty remains for this sector.
The demand for stem cells will remain steady, with market competition and greater ease of obtaining pluripotent cells, keeping prices down. Drug development and disease progression studies will make increasing use of stem cells, and of the various proprietary technologies needed to best study them.
More information can be found in the report “Biobanking for Medical R&D: Technology and Market 2010-2025” by Visiongain.
To order the report or ask for sample pages contact firstname.lastname@example.org
Tel: +44 208 144 6009
Fax: +44 207 900 3970